Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Patients With Severely Reduced Ejection Fraction Undergoing Revascularization—Is Something Missing?

Patients With Severely Reduced Ejection Fraction Undergoing Revascularization—Is Something Missing? Letters 3. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. OAC for the first months after PCI, across risk strata. How- Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl ever, until these trials are complete, the current updated J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482 meta-analysis reaffirms that a NOAC-based strategy on back- 4. Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with ground clopidogrel is a reasonable antithrombotic regimen to atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. find the sweet spot and minimize the risk of severe ischemic 2020;141(9):781-783. and bleeding events in this high-risk population. 5. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of Renato D. Lopes, MD, PhD non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Amit N. Vora, MD, MPH Eur Heart J. 2019;40(46):3757-3767. doi:10.1093/eurheartj/ehz732 John H. Alexander, MD, MHS Author Affiliations: Duke Clinical Research Institute, Duke University Medical In Reply We appreciate the perspective of Reinstadler and Center, Durham, North Carolina (Lopes, Vora, Alexander); UPMC Pinnacle, colleagues regarding the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Patients With Severely Reduced Ejection Fraction Undergoing Revascularization—Is Something Missing?

JAMA Cardiology , Volume 6 (2) – Feb 14, 2021

Loading next page...
 
/lp/american-medical-association/patients-with-severely-reduced-ejection-fraction-undergoing-AczAdsFO3A
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.4873
Publisher site
See Article on Publisher Site

Abstract

Letters 3. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. OAC for the first months after PCI, across risk strata. How- Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl ever, until these trials are complete, the current updated J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482 meta-analysis reaffirms that a NOAC-based strategy on back- 4. Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with ground clopidogrel is a reasonable antithrombotic regimen to atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. find the sweet spot and minimize the risk of severe ischemic 2020;141(9):781-783. and bleeding events in this high-risk population. 5. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of Renato D. Lopes, MD, PhD non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Amit N. Vora, MD, MPH Eur Heart J. 2019;40(46):3757-3767. doi:10.1093/eurheartj/ehz732 John H. Alexander, MD, MHS Author Affiliations: Duke Clinical Research Institute, Duke University Medical In Reply We appreciate the perspective of Reinstadler and Center, Durham, North Carolina (Lopes, Vora, Alexander); UPMC Pinnacle, colleagues regarding the

Journal

JAMA CardiologyAmerican Medical Association

Published: Feb 14, 2021

References